Author:
Gagné-Thivierge Cynthia,Kukavica-Ibrulj Irena,Filion Geneviève,Dekimpe Valérie,Tan Sok Gheck E.,Vincent Antony T.,Déziel Éric,Levesque Roger C.,Charette Steve J.
Funder
Institut universitaire de cardiologie et de pneumologie de Québec
Institute of Infection and Immunity
Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
Cystic Fibrosis Canada
CIHR-Joint Programming Initiative on Antimicrobial Resistance team grant
Canada Research Chairs
Fonds de Recherche du Québec-Santé
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference29 articles.
1. Harun SN, Wainwright C, Klein K, Hennig S. A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatr Respir Rev. 2016;20:55–66.
2. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D’Argenio DA, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA. 2006;103:8487–92.
3. Sousa AM, Pereira MO. Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs—a review. Pathogens. 2014;3:680–703.
4. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348:639–42.
5. Kukavica-Ibrulj I, Bragonzi A, Paroni M, Winstanley C, Sanschagrin F, O’Toole GA, et al. In vivo growth of Pseudomonas aeruginosa strains PAO1 and PA14 and the hypervirulent strain LESB58 in a rat model of chronic lung infection. J Bacteriol. 2008;190:2804–13.